Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors - Scorecard - DentalSpire

Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors

  • By

  • Hana Misganaw

  • Mebratu Tamir

  • Yalewayker Tegegne

  • Zufan Yiheyis Abriham

  • Dereje Mengesha Berta

  • Bisrat Birke Teketelew

  • Negesse Cherie

  • Tsedenya Gebeyehu

  • Elias Chane

  • Abiy Ayele Angelo

  • Aberham Abere

  • Abebaw Setegn

  • Tegegne Eshetu

  • January 30, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of a Single Dose of Albendazole for Treating Ascaris lumbricoides in Schoolchildren in Northwest Ethiopia: An Open-Label Trial Examining Re-Infection Rates and Contributing Factors

At a Glance

CategoryDetail
Condition
Key MechanismsTransmission via fecal-oral route; impacts digestion and absorption of nutrients, leading to malnutrition and other health issues.
Target Population
Care Setting

Key Highlights

  • A. lumbricoides is a major soil-transmitted helminth affecting schoolchildren.
  • Single-dose Albendazole (400 mg) is commonly used for treatment.
  • Re-infection can occur as early as 2 months post-treatment.
  • Efficacy monitoring is crucial due to potential drug resistance.
  • Poor hygiene and sanitation practices contribute to ongoing transmission.
  • Hygiene education is essential to prevent re-infection.

Guideline-Based Recommendations

Diagnosis

  • Microscopic confirmation of A. lumbricoides infection using Kato-Katz technique.

Management

  • Mass drug administration (MDA) of Albendazole for at-risk populations.
  • Implement hygiene education alongside MDA.

Monitoring & Follow-up

  • Regular assessment of drug efficacy and re-infection rates, including specific monitoring protocols.

Risks

  • Potential emergence of drug-resistant A. lumbricoides strains.

Patient & Prescribing Data

School-age children (7-14 years) with confirmed A. lumbricoides infection.

Single-dose Albendazole is effective but requires monitoring for re-infection, including follow-up assessments.

Clinical Best Practices

  • Implement hygiene education alongside MDA to reduce transmission.
  • Conduct periodic evaluations of drug efficacy and resistance.
  • Target interventions based on identified risk factors for re-infection.
  • Engage the community in hygiene education initiatives.

References

Original Source(s)

Related Content